Doctor's Guide -- CHICAGO -- October 11, 2010 -- Postmenopausal women treated with bazedoxifene (BZA), a novel tissue-selective oestrogen complex, plus conjugated oestrogens (CE) experienced better menopause-related quality of life and satisfaction with treatment, according to findings presented here at the 21st Annual Meeting of the North American Menopause Society (NAMS).